Hepatitis Monthly

Published by: Kowsar

Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B

Yue-Li Xiong 1 , Hu Li 1 , Fen Liu 1 , Dazhi Zhang 1 , Hong Ren 1 and Peng Hu 1 , *
Authors Information
1 Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
Article information
  • Hepatitis Monthly: April 01, 2016, 16 (4); e35357
  • Published Online: April 19, 2016
  • Article Type: Brief Report
  • Received: December 9, 2015
  • Revised: January 27, 2016
  • Accepted: February 27, 2016
  • DOI: 10.5812/hepatmon.35357

To Cite: Xiong Y, Li H, Liu F, Zhang D, Ren H, et al. Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B, Hepat Mon. 2016 ; 16(4):e35357. doi: 10.5812/hepatmon.35357.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
  • 2. European Association for the Study of the Liver . EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
  • 3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2[DOI][PubMed]
  • 4. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(3): 531-61[DOI][PubMed]
  • 5. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013; 57(1): 399-408[DOI][PubMed]
  • 6. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol. 2000; 32(2): 300-6[PubMed]
  • 7. Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2009; 50(2): 289-95[DOI][PubMed]
  • 8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005; 352(26): 2673-81[DOI][PubMed]
  • 9. Hadziyannis S, Sevastianos V, Rapti I. 18 Outcome OF HBeAg-Negative Chronic Hepatitis B (CHB) 5 Years After Discontinuation of Long Term Adefovir Dipivoxil (ADV) Treatment. J Hepatol. 2009; 50[DOI]
  • 10. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2010; 52(4): 493-500[DOI][PubMed]
  • 11. Perry CM, Jarvis B. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C. BioDrugs. 2002; 16(3): 213-7[PubMed]
  • 12. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365(9454): 123-9[DOI][PubMed]
  • 13. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352(26): 2682-95[DOI][PubMed]
  • 14. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351(12): 1206-17[DOI][PubMed]
  • 15. Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006; 101(11): 2523-9[DOI][PubMed]
  • 16. Sun J, Hou JL, Xie Q, Li XH, Zhang JM, Wang YM, et al. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther. 2011; 34(4): 424-31[DOI][PubMed]
  • 17. Zhang XQ, Zhang HY, You JP, Mao Q. Efficacy of pegylated interferon alpha2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. Virol J. 2013; 10: 21[DOI][PubMed]
  • 18. Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011; 54(5): 1591-9[DOI][PubMed]
  • 19. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009; 137(6): 2002-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments